revised 3 February 2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
sort code,NSC,Generic Name,Brand Name(s),Target/MOA,"MW (free base/acid, no hydrate)",Dose,Dose Unit,Route,infusion,dose schedule,Cmax (uM),Cmax (mol/liter),Cmax (g/l),Cmax (raw units),Tmax,T1/2,AUC,Cl,Vd,Protein binding,"Css, ave",Initial U.S. approval,Reference,Indication,Notes,,,,,,,,,,unit list,route list
1,748121,Abiraterone Acetate  ,Zytiga ,androgen synthesis inhibitor (CYP17),392,1000,mg,PO,,qd,LLOQ,,,< 0.2 ng/ml,,,,,,-,,2011,Drug Product Label,"prostate cancer:  metastatic castration-resistant prostate cancer, in combination with prednisone",pro-drug for Abiraterone.  Approved 2011; indicated for use in combination with prednisone.,,,,,,,,,,mg/kg,IV
2,749226,*Abiraterone,(Zytiga),androgen synthesis inhibitor (CYP17),350,as above,,,,,0.647,6.47E-07,0.000226,226 ng/ml,,12 h,1173 ng•hr/ml,,19669 L,>99%,,2011,Drug Product Label,"prostate cancer:  metastatic castration-resistant prostate cancer, in combination with prednisone",metabolite of Abiraterone Acetate  ,,,,,,,,,,units/m2,I Cisternal
3,750691,Afatinib,Gilotrif,"kinase inhibitor (Tyrosine): EGFR, HER2, HER4",486,40,mg,PO,,qd,0.0519,5.19E-08,0.0000252,25.2 ng/ml,3.98 h,26.9 h,324 ng•hr/ml,952 ml/min,2220 L,95%,,2013,Clin Pharmacokinet published online June 28 2013  DOI 10.1007/s40262-013-0091-4,NSCLC:  non-small cell lung cancer (metastatic) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations,"irreversible inhibitor.  FDA approved afatinib (Gilotrif tablets, Boehringer Ingelheim Pharmaceuticals, Inc.), for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.  The safety and efficacy of afatinib have not been established in patients whose tumors have other EGFR mutations.  Concurrent with this action, FDA approved the therascreen EGFR RGQ PCR Kit (QIAGEN) for detection of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.  July 12, 2013 More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm360574.htm",,,,,,,,,,mg/day,IM
4,,Alfuzosin HCl ,UroXatral,alpha1 antagonist,389,10,mg,PO,,qd,0.035,3.49E-08,0.0000136,13.6 ng/ml,8,10 h,194 ng•hr/ml,,3.2 L/kg,82-90%,,2003,Drug Product Label,Prostate: benign prostatic hyperplasia (not approved for cancer indications),not approved for cancer indications: indicated for the treatment of signs and symptoms of benign prostatic hyperplasia,,,,,,,,,,mg/m2,topical
5,1390,Allopurinol,"Zyloric, Lopurin, Zyloprim",Nucleoside/Antimetab: Xanthine Oxidase Inhibitor,136,300,mg,PO,,qd,14.253,1.43E-05,0.00194,1936 ng/ml,1.4 h,1.4 h,4814 ng•hr/ml,,,negligible,,1966,"J Clin Pharm Ther 2001, 26(2): 113","Leukemia, lymphoma and malignancies: management of patients who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels.","xanthine oxidase inhibitor indicated for management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels.  Active metabolite oxipurinol (alloxanthine),  also is an inhibitor of xanthine oxidase, with Cmax of 6.5 ug/ml and T1/2 of 15 hours.",,,,,,,,,,mg,PO
6,13875,Altretamine,Hexalen,Alkylating/DNA damage,210,200,mg,PO,,,3.7569,3.76E-06,0.00079,790 ng/ml,0.5-3 h,4.7- 10.2 h,,,,94%,,1990,Pharm Weekbl Sci 1989; 11:218-223,Ovarian cancer: following first-line therapy with a cisplatin and/or alkylating agent-based combination.,Cmax varies widely with formulation; Hexalen @ 200 mg po gave 277 ng/ml,,,,,,,,,,,
7,296961,Amifostine,Ethyol,ROS Scavenger,214,200,mg/m2,IV,7.5 min,,104.900,1.05E-04,0.022471678,104.9 umol/L,,15.4 min,1187 umol•min/L,1.48 L/min,,negligible,,1995,"J Clin Pharmacol 2002, 42(2): 166",Ovarian cancer: reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.,Indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.  Less than 10% of parent remains in the plasma 6 minutes after drug administration. Parent is rapidly metabolized by alkaline phosphatase to an active free thiol metabolite (WR-1065).,,,,,,,,,,,
8,330915,Aminoglutethimide,"Cytadren, Orimeten",Aromatase Inhibitor,232,500,mg,PO,,,25.400,2.54E-05,0.0059,5.9 ug/ml,1.5 h,12.5 h,,,,21-25%,,1980,Drug Product Label,Cushing's syndrome,,,,,,,,,,,,
9,18509,Aminolevulinic Acid  ,Levulan,photosensitizer,131,100,mg,IV,,,128.880,1.29E-04,0.0169,16.9 ug/ml,,50 min,13.7 ug•hr/ml,7.8 L/h,9.3 L,,,1999,"J Pharmacol Exp Ther 2002, 301(2): 507",Actinic Keratosis of the face or scalp (Topical),"preferred route is intravesiclular for bladder cancer: dose  of 1.33 grams  gave 5.35 mg/ml urine, diluted by urine from target concentration of 24 mg/ml.  Oral admin: 100 mg p.o. gave Cmax of 4.6 ug/ml.",,,,,,,,,,,
10,719344,Anastrozole  ,Arimidex ,Aromatase Inhibitor,293,1,mg,PO,,qd,0.035,3.48E-08,0.0000102,10.2 ng/ml,,41.3 h,536 ng•hr/ml,,,40%,,1995,"J Pharm Biomed Anal 2008, 48(3): 853",Breast Cancer:   locally advanced or metastatic;   hormone receptor-positive early breast cancer.,"Anastrozole mean steady-state minimum plasma concentrations in Caucasian and Japanese postmenopausal women who received 1 mg of anastrozole daily for 16 days were 25.7 and 30.4 ng/mL, respectively.",,,,,,,,,,,
11,92859,Arsenic Trioxide  ,Trisenox ,not defined; Apoptosis Inducer,198,0.1,mg/kg,IV,2 h,,0.910,9.10E-07,0.00018,0.18 ug/ml,,,,,562 L,75%,,2000," Blood 2001, 98(2): 266-271;  also see Blood 1996, 88(3): 1052; and Drug Product Label","Leukemia: acute promyelocytic leukemia (APL) refractory to  retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.","Immediately hydrolyzed to arsenious acid (AsIII)., the pharmacologically active species of arsenic trioxide.  Following once daily doses of 0.15 mg/k, the daily exposure to AsIII (mean AUC0-24) was 194 ng·hr/mL (n=5) on Day 1 of Cycle 1 and 332 ng·hr/mL (n=6) on Day 25 of Cycle 1, which represents an approximate 2-fold accumulation.",,,,,,,,,,,
12,757441,Axitinib,Inlyta,"kinase inhibitor (Tyrosine): VEGFR, PDGFR",386,5,mg,PO,,BID,0.163,1.63E-07,0.000063,63 ng/ml,1.8 h,3.1 h,466 ng•hr/ml,43 L/h,182 L,>99%,,2012,"J Clin Oncol 2005, 23(24): 5474",renal cell carcinoma (RCC) after failure of one prior systemic therapy,approved 1/27/12;  data reported following 29 days of dosing,,,,,,,,,,,
13,102816,Azacitidine  ,"Vidaza,  Mylosar",Nucleoside/Antimetab: demethylating agent; DNA Methyltransferase (DNMT) Inhibitor,244,75,mg/m2,SC, ,qd X 7,3.071,3.07E-06,0.00075,750 ng/ml,0.5 h,41 min,,167 L/h,76 L,,0.000038495,2004,"Drug Product Label;  J Clin Pharmacol 2005, 45(5): 597","Myelodysplastic Syndromes (MDS):  French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).",IV Cmax was 2750 ng/ml;  AUC similar to SC; F= 89%,,,,,,,,,,,
14,,Belinostat,Beleodaq,HDAC inhibitor,318,1000,mg/m2,IV,30 min,qd X 5 X 3 wk,134.0,1.34E-04,0.042657,42657 ng/ml,,1.0 h,29005 ng•hr/ml,37.6 L/h/m2,16.5 L/m2,94%,,2014,FDA NDA 206256: Clinical Pharmacology and Biopharmaceutics Review,Lymphoma: peripheral T-cell lymphoma (PTCL): relapsed or refractory,approved 7/3/2014,,,,,,,,,,,
15,138783,Bendamustine HCl  ,Treanda ,Alkylating/DNA damage,358,120,mg/m2,IV, 60 min,,16.301,1.63E-05,0.00584,5839 ng/ml,,0.7 h,13635 ng•hr/ml,31.7 L/h,40 L,94-96%,,2008,"Cancer Chemother Pharmacol 2010, 66(6): 1039",Leukemia: Chronic Lymphocytic Leukemia (CLL);  Non-Hodgkin Lymphoma (NHL),,,,,,,,,,,,
16,741061,Bexarotene  ,Targretin ,RXR agonist,348,300,mg/m2,PO,,,3.386,3.39E-06,0.00118,1182 ng/ml,2.5 h,3.4 h,5980 ng•hr/ml,,,>99%,,1999,"J Clin Oncol 2001, 19(9): 2456",Lymphoma: cutaneous T-cell lymphoma,,,,,,,,,,,,
17,722665,Bicalutamide,Casodex,Androgen Receptor Agonist,430,50,mg,PO,,qd,1.780,1.78E-06,0.000768,0.768 ug/ml,31.3 h,139 h,230838 ug•hr/L,0.32 L/h,,96%,,1995,"Drug Product Label; AUC from Clin Ther. 2009, 31:3000–3008","prostate cancer: metastatic carcinoma of the prostate, in combination with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2.",combo with LHRH antagonist,,,,,,,,,,,
18,125066,Bleomycin,Blenoxane,DNA synthesis inhibitor,1416,15,mg/m2,IV,bolus,,706,7.06E-04,1,1 mg/mL,,4 h,299.5 mg•min/ml,50.5 ml/min/m2,17.5 L/m2,1%,,1973,"Cancer Chemother. Pharmacol. 1, 177-181 (1978)","Squamous Cell Carcinoma (Head and neck);  Lymphomas (Hodgkin's Disease, non-Hodgkin's lymphoma);   Testicular Carcinoma; Malignant Pleural Effusion","value from graphic, estimated to C0; 1 unit = 1 mg ",,,,,,,,,,,
19,756655,Bortezomib  ,Velcade ,Proteosome inhibitor,384,1.3,mg/m2,IV,bolus,2x/wk x 2 wk,0.312,3.12E-07,0.00012,120 ng/ml,0.08 h,48.7 h,196 ng•hr/ml,25.9 L/h,1465 L,83%,5.29166666666667E-006,2003,"Clin Pharmacokin 2009, 48(3): 199",Multiple Myeloma; Mantle Cell Lymphoma,Data are for Day 8,,,,,,,,,,,
20,765694,Bosutinib,Bosulif,"kinase inhibitor (Tyrosine): BCR-Abl, Src",530,500,mg,PO,,qd,0.377,3.77E-07,0.0002,200 ng/ml,4-6 h,22.5 h,3650 ng•hr/ml,189 L/h,6080 L,96%,,2012,Drug Product Label,"Leukemia: chronic myelogenous leukemia:   chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) CML with resistance or intolerance to prior therapy.",,,,,,,,,,,,
21,750,Busulfan,Busulflex,Alkylating/DNA damage,246,0.8,mg/kg,IV,2 h,q. 6 h,4.962,4.96E-06,0.001222,1222 ng/ml,,,1167 umol•min/L,2.52 ml/min/kg,0.64 L/kg,32%,8.10416666666667E-007,1954,Drug Product Label,Leukemia: chronic myelogenous leukemia:  for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation., *protein binding is irreversible,,,,,,,,,,,
22,761432,Cabazitaxel  ,Jevtana ,Tubulin: microtubule stabilizing,836,25,mg/m2,IV,1 h,q. 3 wk,0.270,2.70E-07,0.000226,226 ng/ml,1 h,95 h,991 ng•hr/ml,48.5 L/h,4864 L,89-92%,,2010,Drug Product Label,prostate cancer:  in combination with prednisone for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.,,,,,,,,,,,,
23,761068,Cabozantinib,Cometriq,"kinase inhibitor (Tyrosine): c-MET, VEGFR2, RET",502,140,mg,PO,,qd,4.606,4.61E-06,0.00231,2310 ng/ml,2-5 h,55 h,41.6 ug•hr/ml,4.4 L/h,349 L,99.70%,,2012,J Clin Oncol. 2011 Jul 1;29(19):2660-6; Drug Product Label,"medullary thyroid cancer (progressive, metastatic)","XL-184; approved 11.30.12 Data are for MTD (175 mg); Recommended dose is 140 mg.  Accumulation of 4-5X (AUC) on repeated dosing.  MTD=175 mg; data given for multiple dosing (day 19);  single dose(175 mg PO) Cmax=544 ng/ml, AUC=7.7 ug.h/ml",,,,,,,,,,,
24,712807,Capecitabine  ,Xeloda ,Nucleoside/Antimetab: Pyrimidine antagonist,359,1250,mg/m2,PO,,BID,21.066,2.11E-05,0.00757,7.57 ug/ml,49 min,26 min,507 ug•min/ml,5.55 L/min,217 L,approx 35%,,1998,"Cancer Chemother Pharmacol 2011, 67(3): 613","Colorectal Cancer,  Breast Cancer",5-FU prodrug.  Total protein binding of parent and metabolites is less than 60%; parent binding to albumin is approx. 35%,,,,,,,,,,,
25,241240,Carboplatin  ,"Paraplatin,  Paraplat",Alkylating/DNA damage,371,400,mg/m2,IV,30 min,,134.771,1.35E-04,0.05,50 ug/ml,30 min,3.0 h,4-6 mg•min/ml**,4.4 L/h,16 L,0%,,1989,"Cancer Chemother Pharmacol 1988, 22(3): 263",Ovarian cancer: Ovarian Carcinoma,"** AUC given is target AUC for carboplatin as single agent;  parent is not bound to plasma protein, but released platinum binds irreversibly",,,,,,,,,,,
26,758252,Carfilzomib,Kyprolis,Proteosome inhibitor  ,720,27,mg/m2,IV,5 min,,5.880,5.88E-06,0.004232,4232 ng/ml,,< 1 h,379 ng•hr/ml,151-263 L/h,28 L,97%,,2012,Drug Product Label,Multiple Myeloma,"ONO-7057, PR-171; approved in USA 07.21.12",,,,,,,,,,,
27,409962,Carmustine  ,BiCNU,Alkylating/DNA damage,214,600,mg/m2,IV,2 h,,19.388,1.94E-05,0.00415,4.15 ug/mL,,,,,,80%,,1977,Hi dose: Clin Cancer Res. 2002 Mar;8(3):698-705.,"Brain tumors (glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors); Multiple myeloma, in combination with prednisone;  Hodgkin’s disease (as secondary therapy in combination with other approved drugs);  Non-Hodgkin’s lymphomas (as secondary therapy in combination with other approved drugs)",600 mg/m2: 4.15 mg/L graphically. Recommended dose is 150-200 mg/m2 IV,,,,,,,,,,,
28,719627,Celecoxib,Celebrex,COX-2 inhibitor,381,400,mg,PO,,BID,4.598,4.60E-06,0.001752,1752 ng/ml,,8.8 h,13049 ng•hr/ml,25.1 L/h,,97%,0.0005437083,1998,"Neuro-Oncol 2008, 10(2): 190",not approved for cancer indications,"not approved for cancer indications. At recommended anti-inflammatory dose (200 mg PO), Cmax= 705 ng/ml, Tmax= 2.8 h, T1/2= 11.2 h, Vss/F=429 L, Cl/F= 27.7 L/h",,,,,,,,,,,
29,776422,Ceritinib,Zykadia,kinase inhibitor (Tyrosine): ALK,558,750,mg,PO,,qd,1.208,1.21E-06,0.000674,674 ng/ml,5.0 h,41 h,"14,000 ng•hr/ml",53.9 L/h,4230 L,97%,,2014,FD NDA 205755: Clinical Pharmacology and Biopharmaceutics Review,"NSCLC: non-small cell lung cancer, ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib",approved 04.29.2014. PK results from multiple dose study.,,,,,,,,,,,
30,3088,Chlorambucil  ,Leukeran,Alkylating/DNA damage,304,0.2,mg/kg,PO,,qd,1.617,1.62E-06,0.000492,492 ng/ml,0.83 h,1.3 h,883 ng•hr/mL,,,99%,3.67916666666667E-005,1957,Drug Product Label,"Leukemia: chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease",,,,,,,,,,,,
31,187208,Chloroquine,Aralen,not defined,320,750,mg,PO,,,0.725,7.25290116046419E-007,0.000232,232 ng/ml,3.7 h,,8385 ng•hr/ml,,,55%,,1949,Eur J Clin Pharmacol (2009) 65:179–189,not approved for cancer indications,not approved for cancer indications; tissues accumulate 200-700 times the plasma level according to Drug Product Label.,,,,,,,,,,,
32,119875,Cisplatin,"Platinol, Platinol-AQ  ",Alkylating/DNA damage,300,80,mg/m2,IV, 1 h,,14.400,1.44E-05,0.004321,14.4 umol/L,,0.44 h,16.4 umol•h/L,,11-12 L/m2,n/a *,,1978,"J Clin Oncol 2002, 20(6): 1657","Testicular Tumors, Metastatic;  Metastatic Ovarian Tumors;  Advanced Bladder Cancer","Data are for intact cisplatin. * Cisplatin does not undergo the instantaneous and reversible binding to plasma proteins. However, the platinum from cisplatin, but not cisplatin itself, becomes bound to several plasma proteins, including albumin, transferrin, and gamma globulin. Three hours after a bolus injection and two hours after the end of a three-hour infusion, 90% of the plasma platinum is protein bound.",,,,,,,,,,,
33,105014,Cladribine,Leustatin,Nucleoside/Antimetab: Adenosine deaminase inhibitor,286,0.09,mg/kg,IV,24 h,continuous for 7 d,0.020,2.00E-08,0.0000057,5.7 ng/ml,,,,663.5 ml/h/kg,,21-25%,5.7 ng/ml,1993,Drug Product Label,Leukemia: Hairy Cell Leukemia,continuous infusion.  Reference for protein binding: Eur J Clin Pharmacol (1994) 46:563-564,,,,,,,,,,,
34,105014,Cladribine,Leustatin,Nucleoside/Antimetab: Adenosine deaminase inhibitor,286,0.12,mg/kg,IV,2 h,,0.168,1.68E-07,0.000048,48 ng/ml,,5.4 h,,978 mL/h/kg,4.5 L/kg,21-25%,,1993,Drug Product Label,Leukemia: Hairy Cell Leukemia,single dose (2 h infusion): Cmax at end of infusion,,,,,,,,,,,
35,606869,Clofarabine  ,"Clolar,  Clofarex",Nucleoside/Antimetab: Ribonucleoside-Diphosphate Reductase Inhibitor;  DNA Polymerase Inhibitor ,304,40,mg/m2,IV,2 h, X 5 d,0.744,7.44E-07,0.000226,226 ng/ml,,4.9 h,931 ng•hr/ml,1.6 L/h/kg,8.8 L/kg,47%,,2004,"J Clin Pharmacol 2011, 51(5): 679",Leukemia: Acute Lymphoblastic Leukemia:  pediatric patients 1 to 21 years old with relapsed or refractory ALL after at least two prior regimens,recommended pediatric dose is 52 mg/m2 IV 2 hr infusion.,,,,,,,,,,,
36,756645,Crizotinib  ,Xalkori ,"kinase inhibitor (Tyrosine): c-Met,  ALK, RON",450,250,mg,PO,,BID,0.913,9.13E-07,0.000411,411 ng/ml,4.0 h,34.9 h,3880 ng•hr/ml,64.5 L/h,4313 L,91%,,2011,FDA NDA 202570:  Clinical Pharmacology and Biopharmaceutic Review,NSCLC: non-small cell lung cancer (metastatic) whose tumors are ALK-positive,data from multiple dose day 15,,,,,,,,,,,
37,26271,Cyclophosphamide  ,"Cytoxan, Neosar   ",Alkylating/DNA damage,261,600,mg/m2,IV,bolus,,128.000,1.28E-04,,128 uM,,3-12 h,51955 umol•min/L,78 ml/min,,20%,,1959,"Cancer Chemother Pharmacol 1994, 33(6): 472","Lymphoma: Malignant lymphomas (Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma);  Multiple myeloma;  Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia, acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children;  Mycosis fungoides (advanced disease);  Neuroblastoma (disseminated disease);  Adenocarcinoma of the ovary;  Retinoblastoma;  Carcinoma of the breast.",,,,,,,,,,,,
38,63878,Cytarabine,"Cytosar-U, Ara-C, Depocyt",Nucleoside/Antimetab: DNA Polymerase inhibitor,243,3000,mg/m2,IV,,,106.000,1.06E-04,,106 uM,,3.82 h,385 umol•h/L,,,13%,,1969,Cancer Res. 1989 Jan 1;49(1):241-7.,Leukemia: acute non-lymphocytic leukemia;  acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia;  meningeal leukemia, targeted Css with constant infusion is 20-35 uM,,,,,,,,,,,
39,764134,Dabrafenib,Tafinlar,"kinase inhibitor (Ser/Thr): BRAF V600E,K,D mutants",520,150,mg,PO,,BID,4.860,4.86E-06,0.002527,2527 ng/ml,2 h,4.8 h,10751 ng•hr/ml,14.0 L/hr,45.5 L,99.70%,,2013,Journal of Clinical Pharmacology 53(9) 955–961 (2013),"Melanoma:  BRAF V600E or V600K Mutation-Positive, Unresectable or Metastatic",approved 05.29.13 for BRAF V600E mutant melanoma,,,,,,,,,,,
40,45388,Dacarbazine  ,DTIC-Dome ,Alkylating/DNA damage,182,200,mg/m2,IV,30 min,,34.415,3.44E-05,0.00627,6.27 ug/ml,,5 h,4.86 mg•hr/L,91.4 L/h,,<5%,0.0002022917,1975,"Anti-Cancer Drugs 2004, 15(5): 495 and Drug Product Label",melanoma: malignant (metastatic); Hodgkin's disease,"enzymatically converted to MTIC via Cyp1A2, 2E1, 1A1",,,,,,,,,,,
41,3053,Dactinomycin,"Cosmegen, Litak, Movectro",DNA binding/RNA polymerase,1255,0.70- 1.50,mg/m2,IV,bolus,,0.020,2.00E-08,0.0000251,25.1 ng/ml,15 min,14-43 h,2.67 mg•min/L,68-203 ml/min/m2,,5%,7.41666666666667E-006,1964,Clin Cancer Res. 2005 Aug 15;11(16):5893-9.,"Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer,  gestational trophoblastic neoplasia;   locally recurrent or locoregional solid malignancies.",,,,,,,,,,,,
42,732517,Dasatinib  ,Sprycel ,kinase inhibitor (Tyrosine):  Multi-Kinases Including Bcr-Abl & Src,488,100,mg,PO,,qd,0.264,2.64E-07,0.000129,129 ng/ml,2.0 h,6.2 h,478 ng•hr/ml,,2505 L,96%,,2006,Clin Cancer Res. 2012;18:5489-98,"Leukemia: Chronic Myeloid Leukemia:  newly diagnosed Philadelphia chromosome-positive (Ph+) CML in chronic phase;  chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib;  Acute Lymphoblastic Leukemia (Ph+ ALL) with resistance or intolerance to prior therapy",,,,,,,,,,,,
43,82151,Daunorubicin HCl  ,"Cerubidine, Daunoxome ",Topo II /DNA binding,564,50,mg/m2,IV,1 h,,0.31000,3.10E-07,,0.31 umol/L,,11 h,1.02 umol•hr/L,0.21 umol/h,,97%,,1987,Ther Drug Monit 2007;29:626–631,"Leukemia: Acute Nonlymphocytic Leukemia (myelogenous, monocytic, erythroid) of adults ;  Acute Lymphocytic Leukemia of children and adults",data are for standard formulation; liposomal formulation yields 100X higher exposure,,,,,,,,,,,
44,127716,Decitabine  ,Dacogen ,Nucleoside/Antimetab: demethylating agent; DNA Methyltransferase (DNMT) Inhibitor,228,15,mg/m2,IV, 3 h,TID X3d,0.323,3.23E-07,0.0000738,73.8 ng/ml,2.49 h,0.62 h,163 ng•hr/ml,125 L/h.m2,71.8 L/m2,<1%,,2006,"Drug Product Label and Cancer Chemother Pharmacol 2008, 61(5): 759-766","Myelodysplastic Syndromes (MDS):  all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).",,,,,,,,,,,,
45,,Degarelix,Firmagon,LHRH antagonist,1632,240,mg,SC,,,0.016,1.61E-08,0.0000262,26.2 ng/mL,2 d,,1054 ng•day/ml,,,90%,,2008,Drug Product Label,prostate cancer,"Forms a depot upon subcutaneous administration, from which degarelix is released to the circulation.",,,,,,,,,,,
46,169780,Dexrazoxane HCl  ,"Totect, Zinecard  ",chelator,268,500,mg/m2,IV,15 min,,136.057,1.36E-04,0.0365,36.5 ug/ml,,2.5 h,,7.88 L/h/m2,22.4 L/m2,<2%,,1995,Drug Product Label; see also:  J Clin Pharmacol. 2011 May;51(5):731-8.  ,Breast Cancer:  reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2,Used as cardioprotectant in combination with doxorubicin,,,,,,,,,,,
47,628503,Docetaxel  ,Taxotere ,Tubulin: microtubule stabilizing,808,100,mg/m2,IV,1 h,,5.471,5.47E-06,0.00442,4.42 ug/ml,,41.0 h,5.9 ug•hr/ml,35 L/h,477 L,97%,,1996,"Clin Pharmacol Ther 2004, 75(5): 448",Breast Cancer;  Non-Small Cell Lung Cancer;  Prostate Cancer;  Gastric Adenocarcinoma;  Head and Neck Cancer,,,,,,,,,,,,
48,123127,Doxorubicin HCl  ,Adriamycin ,Topo II /DNA intercalating,544,60,mg/m2,IV,5 min,,6.734,6.73E-06,0.00366,3.66 ug/ml,,14.2 h,1.85 ug•hr/ml,,762 L/m2,75%,,1974,"Anti-Cancer Drugs 1999, 10(8): 719","Breast Cancer (adjuvant of multi-agent chemotherapy),  Acute Lymphoblastic Leukemia;  Acute Myeloblastic Leukemia;  Hodgkin lymphoma;  non-Hodgkin lymphoma (NHL);  Metastatic: breast cancer, Wilms' tumor, neuroblastoma, soft tissue sarcoma, bone sarcoma,  ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma,  gastric carcinoma, bronchogenic carcinoma",,,,,,,,,,,,
?????,,Dutasteride,Avodart,5-alpha reductase inhibitor,,,,,,,,,,,,,,,,,,2001,,Prostate: benign prostatic hyperplasia (not approved for cancer indications),SHOULD THIS BE ADDED? not approved for cancer indications: Approved for BPH,,,,,,,,,,,
49,755605,Enzalutamide,Xtandi,Androgen Receptor Agonist,464,160,mg,PO,,qd,35.742,3.57E-05,0.0166,16.6 ug/ml,1 h,5.8 d,,0.56 L/h,110 L,98%,,2012,Drug Product Label,Prostate Cancer:  metastatic castration-resistant prostate cancer who have previously received docetaxel,"approved 08.31.12.  Active metabolite (CYP2C8, 3A4) is N-desmethyl enzalutamide, Cmax is 12.7 ug/ml.  previously named MDV 3100",,,,,,,,,,,
50,256942,Epirubicin HCl  ,Ellence ,Topo II,544,120,mg/m2,IV,,,16.558,1.66E-05,0.009,9.0 ug/ml,,33.7 h,3.4 ug•hr/ml,65 L/h,23 L/kg,77%,,1999,Drug Product Label,Breast Cancer: as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer,,,,,,,,,,,,
51,707389,Eribulin Mesylate  ,Halaven ,Tubulin: inhibition,730,1.4,mg/m2,IV,2-5 min,,0.508,5.08E-07,0.000371,371 ng/ml,0.17 h,40.4 h,757 ng•hr/ml,3.41 L/h,134 L,49-65%,,2010,"Br J Clin Pharmacol 2012, 75:507-515",Breast Cancer: metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease,,,,,,,,,,,,
52,718781,Erlotinib HCl  ,Tarceva ,kinase inhibitor (Tyrosine): EGFR,393,150,mg,PO,,qd,3.147,3.15E-06,0.001238,1.238 ug/ml,5.5 h,24.4 h,18.6 ug•hr/L,6.33 L/h,136 L,93%,,2004,"J Clin Oncol 2001, 19(13): 3267-3279; and  Drug Product Label ",NSCLC: Non-Small Cell Lung Cancer;  Pancreatic Cancer,,,,,,,,,,,,
53,702294,Estramustine phosphate,Emcyt,Alkylating/DNA damage; Tubulin  inhibitor ,520,2000,mg/m2,IV,60 min,qw,796.887,7.97E-04,0.4147,797 umol/L,,2.5 h,1710 umol•hr/L,4.6 L/h,10.3 L,,,1980,"J Clin Oncol 2002, 20(4): 1115",Prostate Cancer:  metastatic and/or progressive carcinoma of the prostate,prodrug for estramustine;  Data are for recommended Phase II dose.  Label recommends 14 mg/kg PO.,,,,,,,,,,,
54,89201,* estramustine,(Emcyt),Alkylating/DNA damage; Tubulin  inhibitor ,425,as above,,,,,10.390,1.04E-05,0.00442,10.4 umol/L,,99 h,88.4 umol•hr/L,,,,,-,"J Clin Oncol 2002, 20(4): 1115",,metabolite of estramustine phosphate,,,,,,,,,,,
55,,* estramustrone,(Emcyt),Alkylating/DNA damage; Tubulin  inhibitor ,424,as above,,,,,15.598,1.56E-05,0.00662,15.6 umol/L,,129 h,498 umol•hr/L,,,,,-,"J Clin Oncol 2002, 20(4): 1115",,metabolite of estramustine phosphate,,,,,,,,,,,
56,141540,Etoposide  ,"Toposar, VePesid ",Topo II /DNA binding,589,100,mg/m2,IV,,,33.404,3.34E-05,0.01966,19.7 mg/L,,4-11 h,,33-48 ml/min,18-29 L,97%,,1983,"Anti-Cancer Drugs 1999, 10(4): 361",Small Cell Lung Cancer;  Refractory Testicular Tumors,Patients received etoposide in combination with cisplatin and Ro 40-8757,,,,,,,,,,,
57,733504,Everolimus  ,Afinitor ,FKBP-12; kinase inhibitor (Ser/Thr): mTOR,958,10,mg,PO,,qd,0.064,6.37E-08,0.000061,61 ng/ml,1 h,,514 ng•hr/ml,,,74%,,2009,"Eur J Cancer 2008, 44(1): 84","Breast Cancer: Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer;  Advanced Neuroendocrine Tumors of Pancreatic Origin (PNET);  Advanced Renal Cell Carcinoma (RCC);  Renal Angiomyolipoma with Tuberous Sclerosis Complex (TSC);  Subependymal Giant Cell Astrocytoma (SEGA) with Tuberous Sclerosis Complex (TSC);  ",,,,,,,,,,,,
58,713563,Exemestane  ,Aromasin ,Aromatase Inhibitor,296,25,mg,PO,, q.d.,0.027,2.67E-08,0.0000079,7.9 ng/ml,1.2-2.9 h,24 h,52 ng•hr/ml,,,90%,,1999,"Breast Cancer Res Treat 2008, 111(2): 377-388 and Drug Product Label",Breast Cancer:  adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen;   Advanced Breast Cancer,Data are following 2 weeks of repeated daily dosing,,,,,,,,,,,
59,757443,Finasteride,Proscar,5-alpha reductase inhibitor,373,5,mg,PO,,qd,0.124,1.24E-07,0.0000462,46.2 ng/ml,1.8 h,6.0 h,389 ng•hr/ml,165 mL/min,76 L,90%,,1992,Drug Product Label,Prostate: benign prostatic hyperplasia (not approved for cancer indications),not approved for cancer indications: Approved for BPH,,,,,,,,,,,
60,27640,Floxuridine,FUDR,Nucleoside/Antimetab: Pyrimidine antagonist,246,30,mg/kg,IV,8 h,,1.052,1.05E-06,0.000259,259 ug/L ; 5-FU was 115 ng/ml,,13 min,81.9 mg•min/L,22.4 L/min,,,,1970,J Clin Pharmacol. 2004 Nov;44(11):1260-72,"gastrointestinal adenocarcinoma metastatic to the liver,",5-FU prodrug.  Cmax varies widely based on dose and infusion rate.,,,,,,,,,,,
61,312887,Fludarabine Phosphate  ,Fludara ,Nucleoside/Antimetab: Adenosine deaminase inhibitor,365,25,mg/m2,IV,30 min,,LLOQ,,,n.d.,,,,,,19-29%,,1991,"Biopharm Drug Dispos 2010, 31(1): 72",Leukemia: B-cell chronic lymphocytic leukemia (CLL),prodrug of 2-F-araA;  Data are for the metabolite (2-fluoro-ara-A); parent is not detectable ,,,,,,,,,,,
62,118218,* 2-F-araA,(Fludara),Nucleoside/Antimetab: Adenosine deaminase inhibitor,269,as above,,,,,3.001,3.00E-06,0.000808,808 ng/ml,,11.3 h,3285 ng•hr/ml,,,,,-,"Biopharm Drug Dispos 2010, 31(1): 72",,"active metabolite of fludarabine phosphate, 2-F-araA",,,,,,,,,,,
63,19893,Fluorouracil  (5-FU),"Adrucil, Efudex,  Carac, Fluoroplex",Nucleoside/Antimetab: Pyrimidine antagonist,130,400,mg/m2,IV,push,,425.902,4.26E-04,0.0554,55.4 ug/ml,,,11.59 ug•hr/ml,30.64 L/h/m2,,10%,,1962,"Pharmacol Res 2004, 50(2): 173","carcinoma of the colon, rectum, breast, stomach and pancreas.",,,,,,,,,,,,
64,147834,Flutamide,Eulexin,Androgen Receptor Antagonist,276,250,mg,PO,,,0.409,4.09E-07,0.000113, 113 ng/ml,1.3 h,7.8 h,,,,94-96%,,1989,Drug Product Label,"prostate cancer, metastatic carcinoma","PK parameters given are after steady state is reached.  Cmax after single dose is 25.2 ng/ml.  Flutamide is rapidly metabolized to the active metabolite, Hydroxyflutamide, which reaches Cmax of 1629 ng/ml at steady state.",,,,,,,,,,,
65,719276,Fulvestrant  ,Faslodex ,Estrogen Receptor Antagonist,607,500,mg,IM,,,0.041,4.14E-08,0.0000251,25.1 ng/ml,,40 d,11400 ng•hr/ml,690 ml/min,3-5 L/kg,99%,,2002,Drug Product Label; see also Br J Cancer. 1996 Jul;74(2):300-8.,Breast Cancer:  hormone receptor positive metastatic breast cancer,,,,,,,,,,,,
66,715055,Gefitinib  ,Iressa ,kinase inhibitor (Tyrosine): EGFR,447,250,mg,PO,,qd,0.356,3.56E-07,0.000159,159 ng/ml,3 h,50.5 h,5115 ng•hr/ml,514 ml/min,1400 L,90%,,2003,Clin Pharmacokinet 2005; 44 (11): 1165-1177,NSCLC: locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies,June 2005: FDA withdrew approval for use in new patients due to lack of evidence that it extended life.,,,,,,,,,,,
67,613327,Gemcitabine HCl  ,Gemzar ,Nucleoside/Antimetab: Pyrimidine antagonist;  DNA synthesis inhibitor,263,1250,mg/m2,IV, 30 min,,89.286,8.93E-05,0.0235,23.5 ug/ml,,0.228 h,12.5 ug•hr/ml,3530 ml/min,25.9 L,negligible,,1996,"Cancer Chemother Pharmacol 2005, 55(6): 522",Ovarian cancer: Breast Cancer;  Non-Small Cell Lung Cancer; Pancreatic Cancer,,,,,,,,,,,,
68,606864,Goserelin acetate implant,Zoladex,GnRH agonist,1269,10.8,mg,SC,,,0.0070,6.97E-09,0.00000885,8.85 ng/ml,1.8 h,,,121 ml/min,44.1 L,27%,,1996,Drug Product Label,prostate cancer.,,,,,,,,,,,,
69,,Histrelin acetate implant,Supprelin,GnRH agonist,1324,0.0567,mg/day,SC,,continuous release over 12 months,0.00083,8.31E-10,0.0000011,1.1 ng/ml,12 h,,13.8 ng.wk/ml,,,70%,0.265 ng/ml,2007,J Clin Pharmacol. 2005 Nov;45(11):1245-9.,prostate cancer.,,,,,,,,,,,,
70,32065,Hydroxyurea,"Hydrea, Droxia",Nucleoside/Antimetab: Ribonucleoside-Diphosphate Reductase Inhibitor,76,2000,mg,PO,,qd,794.750,7.94E-04,,794.75 umol/L,1.22 h,3.32 h,3934 umol•hr/L,124.83 ml/min,19.65 L/m2,,,1968,"Blood 1998, 91(5): 1533","Melanoma, resistant Chronic Myelocytic Leukemia, and recurrent, metastatic, or inoperable Carcinoma of the Ovary,  Head and Neck primary squamous cell (epidermoid) carcinomas","see also:  J Clin Oncol 2005, 23(36): 9359",,,,,,,,,,,
71,722623,Ibandronate sodium,Boniva,osteoclast inhibitor,319,6,mg,IV,,,1.024,1.02E-06,0.000327,327 ng/ml,37.5 min,12 h,56.5 ug•min/ml,141 ml/min,> 90 L,86%,,2003,"J Clin Pharmacol 2007, 47(8): 942",not approved for cancer indications;  Postmenopausal Osteoporosis,not approved for cancer indications;  approved for the treatment of osteoporosis in postmenopausal women,,,,,,,,,,,
72,761910,Ibrutinib,Imbruvica,kinase inhibitor (Tyrosine): Btk (irreversible),441,560,mg,PO,,q.d.,0.277,2.77E-07,0.000122,122 ng/ml,2 h,9.2 h,1263 ng•hr/ml,1000 L/h,10000 L,98%,,2013,FDA NDA 205552: Clinical Pharmacology and Biopharmaceutics Review,Lymphoma: Mantle Cell Lymphoma;  Chronic Lymphocytic Leukemia;  Chronic Lymphocytic Leukemia with 17p deletion; Waldenstrom’s macroglobulinemia (WM),approved 11.13.13.  PK data from multi-dose study #1104-CA,,,,,,,,,,,
73,256439,Idarubicin,Idamycin,Topo II /DNA binding,498,15,mg/m2,IV,5 min,,0.123,1.23E-07,0.0000612,61.2 ng/ml,,21.8 h,173 ng•hr/ml,,,97%,,1990,Cancer Chemother Pharmacol. 2004 Jan;53(1):61-7,Leukemia: acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7,"Idarubicinol (active metabolite) Cmax= 10.4 ng/ml (20.8 nM), T1/2= 47 hr, AUC= 747 ng.hr/ml",,,,,,,,,,,
74,759224,Idelalisib ,Zydelig ,kinase inhibitor: PI3K delta,415,150,mg,PO,,BID,5.180,5.18E-06,0.002152,2152 ng/ml,1.75 h,5.75 h,9599 ng•hr/ml,14.9 L/h,23 L,84%,,2014,FDA NDA 206545: Clinical Pharmacology and Biopharmaceutics Review,Leukemia: Relapsed Chronic Lymphocytic Leukemia;   Relapsed Follicular B-cell non-Hodgkin Lymphoma;   Relapsed Small Lymphocytic Lymphoma,Approved 7/23/14.   Values for Cl and Vd from Drug Product Label,,,,,,,,,,,
75,109724,Ifosfamide  ,"Ifex,  Cyfos,  Ifosfamidum ",Alkylating/DNA damage,261,3000,mg/m2,IV, 3 h,,431.000,4.31E-04,,431 uM,,4.1 h,9379 umol•h/L,,,negligible,,1988,"Cancer Chemother Pharmacol 2007, 60(3): 375",testicular cancer (germ cell),"with 24 h infusion, Cmax is 163 uM.",,,,,,,,,,,
76,743414,Imatinib Mesylate,Gleevec,"kinase inhibitor (Tyrosine): BCR-Abl, Kit, PDGFR",494,600,mg,PO,,,7.496,7.50E-06,0.0037,3.7 ug/ml,,17 h,48.8 ug•hr/ml,8-14 L/hr,,95%,,2001,"Clin Cancer Res 2003, 9(16): 5880",Leukemia: Chronic Myeloid Leukemia: Philadelphia Positive (Ph+ CML);  Acute Lymphoblastic Leukemia: Ph+ ALL;  Myelodysplastic/Myeloproliferative Diseases (MDS/MPD): associated with PDGFR gene re-arrangements;  Aggressive Systemic Mastocytosis (ASM);  Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL);   Dermatofibrosarcoma Protuberans (DFSP);   Kit+ Gastrointestinal Stromal Tumors (GIST);  Adjuvant Treatment of GIST,,,,,,,,,,,,
77,369100,Imiquimod  ,Aldara ,TLR7 Receptor Agonist,240,75,mg,topical,,3X/wk for 16 wk,0.0056,5.62E-09,0.00000135,1.35 ng/ml,,,29.1 ng•hr/L,,,90-95%,,1997,"Arch Dermatol Res 2004, 296(1): 6",Actinic Keratosis;   Superficial Basal Cell Carcinoma,"Cmax is mean at end of 16 week treatment. As topical agent, local tissue concentrations may be much greater than systemic exposure.",,,,,,,,,,,
78,616348,Irinotecan HCl  ,Camptosar ,Topo I/DNA binding,587,340,mg/m2,IV,90 min,,5.782,5.78E-06,0.003392,3392 ng/ml,,11.7 h,20604 ng•hr/ml,13.9 L/hr/m2,234 L/m2,30-68%,,1996,Drug Product Label,colon: metastatic carcinoma of the colon or rectum.,prodrug of SN-38,,,,,,,,,,,
79,673596,* SN-38,(Camptosar),Topo I/DNA binding,392,as above,,,,(Irinotecan),0.143,1.43E-07,0.000056,56 ng/ml,,21.0 h,474 ng•hr/ml,,,95%,,-,Drug Product Label; see also J Clin Oncol 14:1128-1135 (1996),colon: metastatic carcinoma of the colon or rectum.,"SN-38 is active metabolite of irinotecan, delivery of SN-38 as liposomal formulation can result in exposure as high as 2100 ng/ml at 40 mg/m2 SN-38",,,,,,,,,,,
80,747973,Ixabepilone  ,Ixempra ,Tubulin: inhibition,507,40,mg/m2,IV,3 h,,0.497,4.97E-07,0.000252,252 ng/ml,,35 h,2143 ng•hr/ml,352 ml/min/m2,1213 L/m2,67-77%,,2007,"Drug Product Label; see also Clin Cancer Res 2004, 10(4): 1289","Breast Cancer: metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine","data are for day 1, cycle 1; from label, 3 hr infusion yielded Cmax= 252 ng/ml",,,,,,,,,,,
81,,Lanreotide,Somatuline Depot,Somatostatin Agonist ,1096,120,mg,SC,,q. 4 weeks,0.007,7.02E-09,0.0000077,7.7 ng/ml,,,,,,,,2007,Drug Product Label,"gastroenteropancreatic neuroendocrine tumors (GEP-NETs): unresectable, well or moderately differentiated, locally advanced or metastatic  ",oncology approval 12/16/2014.  Cmax at steady state.,,,,,,,,,,,
82,745750,Lapatinib,Tykerb ,"kinase inhibitor (Tyrosine): ERBB2,  EGFR",581,1250,mg,PO,,q.d. X 21 d,4.182,4.18E-06,0.00243,2.43 ug/ml,4 h,14.2 h,36.2 ug•hr/ml,,,>99%,,2007,"Drug Product Label; see also J Clin Oncol 2005, 23(23): 5305","Breast Cancer:  in combination with capecitabine for advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab",,,,,,,,,,,,
83,747972,Lenalidomide  ,Revlimid ,TNF-alpha Production Inhibitor,259,25,mg,PO,,qd,1.740,1.74E-06,0.000451,451 ng/ml,1.5 h,5.3 h,3820 ng•hr/ml,192 ml/min,57.9 L,30%,,2005,"J Clin Pharmacol 2009, 49(6): 650","Multiple Myeloma,  Myelodysplastic Syndromes,   Mantle Cell Lymphoma",,,,,,,,,,,,
84,719345,Letrozole  ,Femara ,Aromatase Inhibitor,285,2.5,mg,PO,,qd,0.406,4.06E-07,,406 nmol/L,1.5 h,,7872 nmol•hr/L,,1.9 L/kg,60%,,1997,"Eur J Cancer 2008, 44(1): 84",Breast cancer,,,,,,,,,,,,
85,377526,Leuprolide Acetate,Eligard,GnRH agonist,1209,30,mg,SC,,q. 4 months,0.124,1.24E-07,0.00015,150 ng/ml,3.3 h,,,8.34 L/h,27 L,43-49%,,1985,"Drug Product Label; see also J
Pharm Sci 1986; 75(2): 158–160",prostate cancer,Subcutaneous delivery provides sustained release.,,,,,,,,,,,
86,79037,"Lomustine,  CCNU",CeeNU,Alkylating/DNA damage,234,130,mg/m2,PO,,qd,LLOQ,,,n.d.,,,,,,50%,,1976,Cancer Chemother Pharmacol (1985) 14:125-131,"Brain tumors (primary and metastatic),  Hodgkin’s disease","Prodrug: measured as sum of cis+trans 4-OH metabolites, the active metabolites following hepatic first-pass.  High dose (Cancer Chemother Pharmacol (1996) 38: 425—430): 15 mg/kg p.o. gave 2.66 mg/L 4-OH-CCNU cis+trans",,,,,,,,,,,
87,,* cis+trans 4-OH-CCNU,(CeeNU),Alkylating/DNA damage,250,as above,,,,,3.392,3.39E-06,0.000847,0.847 mg/L (cis+trans),2-4 h,1.8 h,3.4 mg•hr/L,,,,,-,Cancer Chemother Pharmacol (1985) 14:125-131,,,,,,,,,,,,,
88,762,Mechlorethamine HCl,"Mustargen, Valchlor, Clearazide, Nitrogen Mustard",Alkylating/DNA damage,193,0.4,mg/kg,IV,,,LLOQ,,,n.d.,,,,,,,,1949,Drug Product Label,"Lymphoma: Hodgkin’s disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, bronchogenic carcinoma and metastatic carcinoma resulting in effusion.",plasma levels are undetectable within minutes of injection,,,,,,,,,,,
89,26386,Medroxyprogesterone acetate,Provera,Progesterone receptor agonist,387,20,mg,PO,,,0.00261,2.61E-09,0.00000101,1.01 ng/ml,2.65 h,12.1 h,6.95 ng•hr/ml,64110 ml/min,78024 L,90%,,1959,Drug Product Label,not approved for cancer indications; ;  secondary amenorrhea and abnormal uterine bleeding;  endometrial hyperplasia,not approved for cancer indications,,,,,,,,,,,
90,71423,Megestrol acetate,Megace,Progesterone receptor agonist,385,800,mg,PO,suspension,q.d.,1.958,1.96E-06,0.000753,753 ng/ml,5 h,,10476 ng•hr/ml,,,,,1971,"Drug Product Label; see also Cancer Chemother Pharmacol 1995, 36(4): 356","Breast cancer, Endometrial carcinoma,  Cachexia associated with AIDS",Data are following 21 day dosing at high dose,,,,,,,,,,,
91,8806,Melphalan,Alkeran,Alkylating/DNA damage,305,20,mg/m2,IV,,,9.2,9.17E-06,0.0028,2.8 ug/mL,,75 min,,7-9 ml/min/kg,0.5 L/kg,60-90%,,1964,"Drug Product Label; for high dose see: Anticancer Res 1997, 17(1B): 605",Multiple Myeloma; epithelial carcinoma of the ovary (oral tablet),IV Melphalan approved 1992,,,,,,,,,,,
92,755,Mercaptopurine,Purinethol,Nucleoside/Antimetab: purine antagonist,152,75,mg/m2,PO,,qd,0.590,5.90E-07,0.00008968,0.59 umol/L,,1.3 h,1.8 umol•h/L,,,19%,,1953,"Blood 1998, 92(10): 3569","Leukemia: acute lymphatic leukemia (lymphocytic, lymphoblastic) ",high inter-patient variability,,,,,,,,,,,
93,755,mercaptopurine,Purixan,Nucleoside/Antimetab: purine antagonist,152,50,mg,PO,suspension,q.d.,0.625,6.25E-07,0.000095,95 ng/ml,,2 h,136 ng•hr/ml,,,19%,,2014,Drug Product Label,Leukemia: acute lymphoblastic leukemia ,suspension formulation approved 04/28/2014 ,,,,,,,,,,,
94,91485,Metformin,Glucophage,not defined,129,1500,mg,PO,,qd,24.001,2.40012387736141E-005,0.0031,3.10 ug/ml,1.5 h,5.98 h,18.4 ug•hr/ml,1552 ml/min,,negligible,,1959,"Br. J. Clin. Pharmac. 1981, 12: 235-246",not approved for cancer indications;  glycemic control in adults and children with type 2 diabetes mellitus,"not approved for cancer indications: Drug Product Label reports Cmax after 850 mg PO dose is 1.60 ug/ml in healthy adults, representing the average of means from five studies. ",,,,,,,,,,,
95,740,Methotrexate  ,"Abitrexate, Folex,  Mexate, Mexate-AQ,  Oxtrexup, Rasuvo, Trexall",Nucleoside/Antimetab: DHFR inhibitor,454,30,mg,PO,,,1.307,1.31E-06,0.000594,594 ug/L,1.2 h,2.9 h,2466 ug•hr/L,8.4 L/h,,50%,,1954,"J Rheumatol 2004, 31(4): 645","gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole;  acute lymphocytic leukemia, meningeal leukemia,  . breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types,  non-Hodgkin's lymphomas,  nonmetastatic osteosarcoma","PK is highly variable, esp. at high doses (>40 mg); Cmax as high as 1000 uM has been reported (Pediatr Pol. 1995 Nov;70(11):929-37)",,,,,,,,,,,
96,45923,Methoxsalen,"8-MOP, Uvadex, Oxsoralen",Alkylating/DNA damage,216,40,mg,PO,,see notes,0.624,6.24E-07,0.000135,178 ng/ml,2.0 h,2.0 h,440 ng•hr/ml,,,90%,,1954,"J Clin Pharmacol 2006, 46(7): 768","Lymphoma: Cutaneous T-cell lymphoma, used in conjunction with extra-corporeal UV irradiation.","Approved 1999 for Cutaneous T-cell lymphoma.  Used in conjunction with extracorporeal UV irradiation with the UVAR instrument:  the white cell layer (buffy coat) is collected by centrifugation; red cells are returned to the patient and the UVADEX Sterile Solution is then injected into the instrument and mixed with the buffy coat. The instrument then irradiates this drug-cell mixture with ultraviolet light (UVA light, 320-400 nm) and returns the treated cells to the patient.",,,,,,,,,,,
97,26980,Mitomycin C,Mutamycin,Alkylating/DNA damage,334,15,mg/m2,IV,30 min,,2.180,2.18E-06,0.000729,729 ng/ml,,0.81 h,691 ng•hr/ml,402 ml/min/m2,24.5 L/m2,24%,,1974,"Cancer 2001, 91(4): 815;   protein binding found in: International Journal of Pharmacology, 2: 293-297 (2006)",Pancreatic cancer: adenocarcinoma of the stomach or pancreas,launched 1956,,,,,,,,,,,
98,38721,"Mitotane,  o,p'-DDD",Lysodren,Adrenocortical steroid inhibitor,320,6000,mg/day,PO,,3-4 divided doses,50.938,5.09E-05,0.0163,16.3 mg/L,,18-159 d,,,,6%,,1970,"J. Clin. Endocrinol. Metab. 2011, 96:1844-1851 ",adrenal cortical carcinoma,Median Cmax of responders is reported.  Plasma exposure above 14 mg/L correlates with clinical response.,,,,,,,,,,,
99,301739,Mitoxantrone HCl,"Novantron, Eslep",Topo II /DNA binding,444,12,mg/m2,IV,30 min,,0.715,7.15E-07,0.000318,318 ng/ml,,17.0 h,298 ng•hr/ml,40.2 L/hr/m2,>1000 L/m2,78%,,1987,Cancer Chemother Pharmacol (2011) 67:431–438,"prostate cancer;   acute nonlymphocytic leukemia (ANLL) in adults,  including myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.",alternate NSC#,,,,,,,,,,,
100,279836,Mitoxantrone HCl,"Novantron, Eslep",Topo II /DNA binding,444,12,mg/m2,IV,30 min,,0.715,7.15E-07,0.000318,318 ng/ml,,17.0 h,298 ng•hr/ml,40.2 L/hr/m2,>1000 L/m2,78%,,1987,Cancer Chemother Pharmacol (2011) 67:431–438,"prostate cancer;   acute nonlymphocytic leukemia (ANLL) in adults,  including myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.",,,,,,,,,,,,
101,755985,Nelarabine  ,Arranon ,Nucleoside/Antimetab: purine antagonist,297,1500,mg/m2,IV,2 h,,16.820,1.68E-05,0.005,5.0 ug/ml,,18 min,4.4 ug•hr/ml,197 L/h/m2,197 L/m2,<25%,,2005,"Drug Product Label; see also J Clin Oncol 1998, 16(11): 3607",Leukemia: T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma,prodrug of ara-G,,,,,,,,,,,
102,76352,* ara-G,(Arranon),Nucleoside/Antimetab: purine antagonist,283,as above,,,,,110.837,1.11E-04,0.0314,31.4 ug/ml,,3.2 h,162 ug•hr/ml,10.5 L/h/m2,50 L/m2,<25%,,-,Drug Product Label,,,,,,,,,,,,,
103,747599,Nilotinib  ,Tasigna ,kinase inhibitor (Tyrosine): BCR-Abl,530,400,mg,PO,,BID,0.840,8.40E-07,0.000445,445 ng/ml,4 h,13 h,11.9 mg•hr/L,50.5 L/h,,98%,,2007,"J Clin Pharmacol 2010, 50(2): 188;  see also J Clin Pharmacol 2011, 51(1): 75",Leukemia: chronic myeloid leukemia (Ph+ CML) ( Philadelphia chromosome positive ),,,,,,,,,,,,
104,684588,Nilutamide,Nilandron,Androgen Receptor Antagonist,317,150,mg,PO,,qd,2.837,2.84E-06,0.0009,0.9 ug/ml,2.8 h,56 h,39 ug•hr/ml,,,80-84%,4.4 mg/L,1996,"Urology 1991, 37(2, Suppl.): 13","Prostate Cancer, Metastatic",steady state concentration at 150 mg daily is approx 5X higher than single dose,,,,,,,,,,,
104,685403,Octreotide acetate,Sandostatin,Somatostatin Agonist ,1033,0.1,mg,SC,,,0.00384,3.84E-09,0.00000397,3.97 ng/ml,0.64 h,2.25 h,12.4 ng•hr/ml,7-10 L/h,13.6 L,65%,,1988,"J Clin Endocrinol Metab, 2012, 97(7):2362–2369; and Drug Product Label","Carcinoid Tumors,  Vasoactive Intestinal Peptide Tumors (VIPomas)",recommended dose is 50 ug SC twice or three times per day,,,,,,,,,,,
105,753686,Olaparib,Lynparza,PARP inhibitor,434,400,mg,PO,,BID,,,,,,11.9 h,,8.6 L/h,167 L,82%,,2014,Drug Product Label,Ovarian cancer: germline BRCA mutated,Approved 12.19.14,,,,,,,,,,,
106,758253,Omacetaxine mepesuccinate,Synribo,protein translation inhibitor:binds ribosomal A-site,546,1.25,mg/m2,SC,,BID X 14 d,0.04600,4.60E-08,0.0000251,25.1 ng/ml,0.55 h,7 h,136.2 ng•hr/ml,13.5 L/h/m2,127 L,50%,,2012,Cancer Chemother Pharmacol (2013) 71:35–41; and Drug Product Label,Leukemia: chronic myeloid leukemia (CML), approved  26 October 2012.  Cmax given for single dose; Cmax at steady state is 36.2 ng/ml. Mechanism:  protein translation inhibitor. It inhibits protein translation by preventing the initial elongation step of protein synthesis. It interacts with the ribosomal A-site and prevents the correct positioning of amino acid side chains of incoming aminoacyl-tRNAs. Omacetaxine acts only on the initial step of protein translation and does not inhibit protein synthesis from mRNAs that have already commenced translation.,,,,,,,,,,,
107,266046,Oxaliplatin  ,Eloxatin ,Alkylating/DNA damage,397,110,mg/m2,IV,2 h,,4.959,4.96E-06,0.00197,1.97 ug/ml,,1.86 h,4.99 ug•hr/ml,,,>90%,,2002,"Ann Oncol 2003, 14(12): 1776 ","colon cancer,  colorectal cancer","Oxaliplatin shows irreversible plasma protein binding of  90%, so values are reported as ultrafilterable platinum.  Drug Product Label recommends dose of 85 mg/m2, reporting Cmax= 0.814 ug/ml.",,,,,,,,,,,
108,,Palbociclib,Ibrance,,,,,,,,,,,,,,,,,,,2015,,,"Feb. 3, 2015",,,,,,,,,,,
109,125973,Paclitaxel  ,Taxol,Tubulin: microtubule stabilizing,854,175,mg/m2,IV,3 h,,4.275,4.27E-06,0.00365,3650 ng/ml,,20.2 h,15007 ng•hr/ml,12.2 L/hr/m2,227-688 L/m2,89-98%,,1992,"Drug Product Label; for comparison with nab-Paclitaxel formulation, see Clin Cancer Res 2008, 14(13): 4200","Ovarian cancer: breast cancer,  non-small cell lung cancer,  AIDS-related Kaposi’s sarcoma.",,,,,,,,,,,,
110,,nab- Paclitaxel,Abraxane,Tubulin: microtubule stabilizing,854,260,mg/m2,IV,30 min,,21.900,2.19E-05,0.01874,18741 ng/ml,,27 h,20324 ng•hr/ml,15 L/hr/m2,632 L/m2,89-98%,,2005,"Drug Product Label; AUC from Clin Cancer Res 2008, 14(13): 4200","Breast cancer (metastatic),  Non-Small Cell Lung Cancer,  Adenocarcinoma of the Pancreas",nanoparticle albumin-bound Paclitaxel.   09/09/2013:  Approved in combination with gemcitabine for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.,,,,,,,,,,,
111,737754,Pazopanib HCl  ,Votrient ,kinase inhibitor (Tyrosine):  VEGF,438,800,mg,PO,,,132.800,1.33E-04,0.0581,58.1 ug/ml,2-4 h,30.9 h,1037 ug•hr/ml,,,>99%,,2009,"Drug Product Label; see also Clin Pharmacol Ther. 2010, 88(6):818-23","renal cell carcinoma (RCC),  soft tissue sarcoma (STS)","significant food effects on bioavailability; food (high- or low-fat) increased Cmax, AUC and variability.",,,,,,,,,,,
112,755384,Pemetrexed,Alimta,Nucleoside/Antimetab: DHFR inhibitor,427,500,mg/m2,IV,10 min,,306.490,3.06E-04,0.131,131 ug/ml,,4.4 h,188 ug•hr/ml,93.2 ml/min,20.2 L,81%,,2004,"J Clin Oncol 2006, 24(4): 552","NSCLC: Nonsquamous Non-Small Cell Lung Cancer,  Mesothelioma",,,,,,,,,,,,
113,218321,Pentostatin,Nipent,Nucleoside/Antimetab: Adenosine deaminase inhibitor,268,4,mg/m2,IV,15 min,,1.823,1.82E-06,0.000489,489 ng/ml,,5.3 h,1232 ng•hr/ml,114 ml/min,20 L/m2,4%,,1991,"Cancer Chemother Pharmacol 2002, 50(2): 121-126.  ",Leukemia: hairy cell leukemia,"Calculated mean Cmax from Table 3 (N=6, normal renal function);  measured by Enzyme assay; alternate LC/UV method (abstract) reports 60 uM with 4 mg/m2 (Proc Am Soc Clin Oncol (ASCO) 2002, 21(Part 2): Abst 479)",,,,,,,,,,,
114,761388,Plerixafor,Mozobil,chemokine (CXCR4) antagonist,503,0.24,mg/kg,SC,,,1.842,1.84E-06,0.000926,926 ng/ml,0.5 h,5.1 h,4741 ng•hr/ml,4767 ml/h,33.7 L,58%,,2008,"Biol Blood Marrow Transplant 2009, 15:39-46, ",Lymphoma: non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM): to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients ,,,,,,,,,,,,
115,775351,Pomalidomide ,Pomalyst,TNF-alpha Production Inhibitor,273,4,mg,PO,,qd,0.274,2.74E-07,0.000075,75 ng/ml,2-3 h,9.5 h,400 ng•hr/ml,7-10 L/h,62-138 L,12-44%,,2013,Drug Product Label,Multiple Myeloma,Approved 02.08.13.  Black box warning for pregnancy.,,,,,,,,,,,
116,758487,Ponatinib,Iclusig,"kinase inhibitor (Tyrosine): BCR-Abl; VEGFR, FGFR, Flt3, Tie2",533,45,mg,PO,,qd,0.137,1.37E-07,0.000073,73 ng/ml,,24 h,1253 ng•hr/ml,,1223 L,>99%,,2012,Drug Product Label,"Leukemia: chronic myeloid leukemia (CML),  acute lymphoblastic leukemia (Ph+ALL) T315I-positive Philadelphia chromosome positive",Approved 12.14.12.   The Food and Drug Administration temporarily suspended sales of the drug in the U.S. on 31 October 2013 because of “the risk of life-threatening blood clots and severe narrowing of blood vessels”.,,,,,,,,,,,
117,603062,Porfimer sodium,Photofrin,photosensitizer,1179,2,mg/kg,IV,3-5 min,,33.917,3.39E-05,0.04,40 ug/ml,,415 h,2400 ug•hr/ml,0.051 ml/min/kg,,90%,,1995,Drug Product Label,"esophageal cancer,  endobronchial non-small-cell lung cancer (NSCLC),  ablation of high-grade dysplasia in Barrett’s esophagus",,,,,,,,,,,,
118,754230,Pralatrexate  ,Folotyn ,Nucleoside/Antimetab: DHFR inhibitor,477,40,mg/m2,IV,5 min,,10.262,1.03E-05,0.0049,4.9 ug/ml,,1.8 h,4.9 ug•hr/ml,417 ml/min (S) and 191 ml/min ®,105(S) and 37(R)  L,67%,,2009,"Cancer Chemother Pharmacol 2006, 57(5): 671",Lymphoma: peripheral T-cell lymphoma (PTCL). ,given with probenecid 70 mg/m2 IV.  Recommended dose is 30 mg/m2.  Drug is mixture of R and S diastereomers,,,,,,,,,,,
119,10023,Prednisone,"Deltasone, Orasone, Delta-dome, Cortan, Fernisone, Meticorten, Paracort, Prednicen-N, Rayos, Servisone",Glucocorticoid,358,50,mg,PO,,,0.145,1.45E-07,0.000052,52 ug/L,,,,,,extensive,,1974,"J Pharmacokinet Biopharm 1981, 9(1): 1","Leukemias and lymphomas in adults,  Acute leukemia of childhood",,,,,,,,,,,,
120,77213,Procarbazine HCl  ,Matulane ,Alkylating/DNA damage,221,300,mg,PO,,,3.127,3.13E-06,0.000692,0.692 ug/ml,0.21 h,0.154 h,0.217 ug•hr/ml,35.8 L/min,435 L,,,1969," Anti-Cancer Drugs 2006, 17(1): 75;  see also Clin Cancer Res 2006, 12(17): 5174",Lymphoma: Hodgkin's disease,,,,,,,,,,,,
121,14229,Quinacrine,Acrichine,NF-kappaB Activation Inhibitor; sPLA2 Inhibitor,400,100,mg,PO,,TID,0.300,3.00E-07,,300-1000 nM,,,,,,80-90%,,1932,Dement Geriatr Cogn Disord 2004;17:158–163,not approved for cancer indications,not approved for cancer indications; discontinued;   plasma levels of up to 2.5 micromolar were observed folloing 84 days of treatment at 300 mg/d;  long t1/2; pronounced tissue accumulation  ,,,,,,,,,,,
122,747974,Raloxifene HCl  ,"Evista, Keoxifene ",Estrogen Receptor agonist/antagonist; SERM,474,60,mg,PO,,,0.0011,1.06E-09,0.0000005,0.5 (ng/ml)/(mg/kg),,27.7 h,27.2 (ng•hr/ml)/(mg/kg),44.1 L/kg.hr,2348 L/kg,95%,,1997,"Drug Product Label; see also Breast Cancer Res Treat 2008, 111(2): 377, giving Cmax at 1.46 ng/ml",Breast Cancer:  Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women,"reported exposure normalized for dose (mg/kg), so exposure calculated for 60 kg patient (1 mg/kg)",,,,,,,,,,,
123,763932,Regorafenib,Stivarga,"kinase inhibitor (Tyrosine): RET/VEGFR/ TIE2, others",483,160,mg,PO,,qd,8.0775,8.08E-06,0.0039,3.9 ug/ml,4 h,28 h,58.3 ug•hr/ml,,,99.50%,,2012,Drug Product Label,"Colorectal Cancer,   Gastrointestinal Stromal Tumors","Approved 09.27.12.  Cmax given for steady state; single dose Cmax is 2.5 ug/ml; AUC 70.4 ug.hr/ml.  Main circulating metabolites of regorafenib measured at steady-state in human plasma are M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl), both of them having similar in vitro pharmacological activity and steady-state concentrations as regorafenib.",,,,,,,,,,,
124,754143,Romidepsin  ,Istodax ,HDAC inhibitor,541,14,mg/m2,IV,4 h,,0.697,6.97E-07,0.000377,377 ng/ml,,3 h,1549 ng•hr/ml,11.6 L/h/m2,8.6 L/m2,92-94%,,2009,"Drug Product Label; see also Clin Cancer Res 2002, 8(3): 718","Lymphoma: cutaneous T-cell lymphoma (CTCL),  peripheral T-cell lymphoma (PTCL)",,,,,,,,,,,,
125,752295,Ruxolitinib,Jakafi,"kinase inhibitor (Tyrosine):  JAK1, JAK2",306,25,mg,PO,,BID,1.093,1.09E-06,,1093 nM,0.63 h,2.3 h,3200 nmol•hr/L,,,97%,,2011,"Drug Metab Dispos 2010, 38(11): 2023",myelofibrosis; polycythemia vera,Dose (5-25 mg BID) is based on platelet count,,,,,,,,,,,
126,744009,Sildenafil,Viagra,PDE-5  cGMP-phosphodiesterase inhibitor,475,100,mg,PO,,,0.794,7.94E-07,0.000377,377 ng/ml,1 h,2.76 h,1295 ng•hr/ml,,105 L,96%,,1998,"Br J Clin Pharmacol 2010,  69 (1): 23–26; see also Br J Clin Pharmacol 2002,  53: 45S-52S; hi dose 200 mg yielded 2.18 uM Cmax.",not approved for cancer indications;  pulmonary arterial hypertension,"not approved for cancer indications:  active metabolite N-desmethyl (via cyp3A4) shows 50% potency, 40% exposure of parent",,,,,,,,,,,
127,226080,Sirolimus (Rapamycin),Rapamune,FKBP-12: kinase inhibitor (Ser/Thr): mTOR,914,2,mg,PO,,,0.0164,1.64E-08,0.000015,15.0 ng/ml,3.5 h,62 h,230 ng•hr/ml,139 ml/hr/kg,12 L/kg,92%,,1999,"Drug Product Label; see also Br J Cancer 2010, 103(11): 1637",not approved for cancer indications; Prophylaxis of Organ Rejection in Renal Transplantation,"not approved for cancer indications: 3A4 substrate; PK strongly influenced by concurrent 3A4 inhibitors, e.g., cyclosporine",,,,,,,,,,,
128,747971,Sorafenib ,Nexavar ,kinase inhibitor (Tyrosine):  Multi-kinase,465,400,mg,PO,,BID,20.115,2.01E-05,0.00935,9.35 mg/L,2.5 h,23.8 h,107 mg•hr/L,,,99.5%,,2005,"J Clin Oncol 2005, 23(5): 965","Hepatocellular Carcinoma,  Renal Cell Carcinoma,  Differentiated Thyroid Carcinoma",Cmax  following multiple dosing,,,,,,,,,,,
129,85998,Streptozocin,Zanosar,Alkylating/DNA damage,265,1500,mg/m2,IV,push,,1438.046,1.44E-03,0.3814,381.4 ug/ml,,13 min,4329 ug•min/ml,478 ug/min,,,,1982,J Clin Pharmacol. 1977 Jul;17(7):379-88,Pancreatic cancer: metastatic islet cell carcinoma of the pancreas.,Maximum single dose is 1500 mg/m2,,,,,,,,,,,
130,750690,Sunitinib Malate  ,Sutent ,kinase inhibitor (Tyrosine):  Multi-kinase,398,50,mg,PO,,q.d. X 28 d,0.181,1.81E-07,0.0000722,72.2 ng/ml,8.5 h,41-86 h,1296 ng•hr/ml,46.4 L/h,2230 L,95%,,2006,"J Clin Oncol 2006, 24(1): 25","Gastrointestinal Stromal Tumor (GIST),  Advanced Renal Cell Carcinoma (RCC),  Advanced Pancreatic Neuroendocrine Tumors (pNET)",Cmax following day 28 of daily administration; first dose Cmax= 27.7 ng/ml,,,,,,,,,,,
131,717865,Tacrolimus,Prograf,FKBP-12; calcineurin inhibitor,804,5,mg,PO,,,0.037,3.69E-08,0.0000297,29.7 ng/ml,1.6 h,34.8 h,243 ng•hr/ml,0.041 L/hr/kg,1.94 L/kg,99%,,1994,Drug Product Label,"not approved for cancer indications;  Prophylaxis of Organ Rejection in Kidney,  Liver and Heart Transplant",not approved for cancer indications,,,,,,,,,,,
132,180973,Tamoxifen Citrate  ,Nolvadex ,Estrogen Receptor Antagonist,372,20,mg,PO,,,0.10767,1.08E-07,0.00004,40 ng/ml,5 h ,5-7 d,,,,>99%,122 ng/ml,1977,Drug Product Label,Breast Cancer (Metastatic);  Ductal Carcinoma in Situ (DCIS):,"see also: Clin Pharmacol Ther 1998, 64(6): 648 80 mg PO dose yields 145 ng/ml",,,,,,,,,,,
133,148958,Tegafur,Utefos,Nucleoside/Antimetab: Pyrimidine antagonist,200,50,mg/m2,PO,,q.d.,18.999,1.90E-05,0.003803,3083 ng/ml,1.0 h,7.88 h,26840 ng•hr/ml,,,,,1972,"Clinical Cancer Research 2002, 8, 2116–2122 ","Breast cancer, Carcinoma of bladder, Head and neck cancer, Liver carcinoma, Malignant tumor of digestive organ, Non-small cell lung cancer, Renal cell carcinoma
","5-FU prodrug; no current Drug Label available; has been used in Breast cancer, Carcinoma of bladder, Head and neck cancer, Liver carcinoma, Malignant tumor of digestive organ, Non-small cell lung cancer, Renal cell carcinoma",,,,,,,,,,,
134,362856,Temozolomide  ,Temodar ,Alkylating/DNA damage,194,150,mg/m2,IV,90 min,,37.600,3.76E-05,0.0073,7.3 ug/ml,1 h,1.8 h,24.6 ug•hr/mL,5.5 L/h/m2,0.4 L/kg,15%,,1999,Drug Product Label; see also Clin Cancer Res. 2004 Mar 1;10(5):1645-56.,"Glioblastoma Multiforme,  Refractory Anaplastic Astrocytoma",Active metabolite MTIC Cmax=276 ng/ml,,,,,,,,,,,
135,407347,* MTIC,(Temodar) ,Alkylating/DNA damage,168,as above,,,,,1.641,1.64E-06,0.000276,276 ng/ml,,,891 ng•hr/ml,,,,,-,Drug Product Label,,non-enzymatically formed from parent at neutral pH,,,,,,,,,,,
135,683864,Temsirolimus  ,Torisel ,FKBP-12; kinase inhibitor (Ser/Thr): mTOR,1030,25,mg,IV,30-60 min,,0.568,5.68E-07,0.000585,585 ng/ml,,17 h,1627 ng•h/mL,,,87%,,2007,Drug Product Label,renal cell carcinoma,Sirolimus is an active metabolite,,,,,,,,,,,
136,122819,Teniposide,Vumon,Topo II ,657,300-750,mg/m2,IV,72 h,,23.148,2.31E-05,0.0152,15.2 mg/L **,,,,,,>99%,15.2 mg/L,1992,"J Clin Oncol 5 (7), 1987: 1007-1014 ",Leukemia: childhood acute lymphoblastic leukemia.,** plasma steady state exposure in responders reported here;  high variability following brief injection; ,,,,,,,,,,,
137,17591,Testosterone enanthate,Delatestryl,Androgen Receptor Agonist,401,800,mg,PO,q.d.,,,,,,,,,,,,,1953,"J Androl 2008, 29(3): 260",Breast Cancer: Metastatic mammary cancer ,REVIEW THIS; LABEL IS FOR IM ADMIN>>prodrug;  exposure reported as testosterone,,,,,,,,,,,
138,,* Testosterone,(Delatestryl),Androgen Receptor Agonist,288,as above,,,,,0.316,3.16E-07,,316 nmol/L,1.3 h,6.9 h,906 nmol•hr/L,,,98%,,-,"J Androl 2008, 29(3): 260",,,,,,,,,,,,,
139,17591,Testosterone enanthate,Delatestryl,Androgen Receptor Agonist,,400,mg,IM,,q. 2-4 wk,,,,,,,,,,,,-,need PK and reference for this (recommended) dose/route,Breast Cancer: Metastatic mammary cancer ,,,,,,,,,,,,
140,66847,Thalidomide  ,Thalomid ,TNF-alpha Production Inhibitor ,258,200,mg,PO,,,8.907,8.91E-06,0.0023,2.30 ug/ml,5.8 h,4.12 h,23.3 ug•hr/ml,9.09 L/h,53 L,55% (+)-(R);  66% (-)-(S),0.94 ug/ml,1998/2006,Clin Pharmacol Ther. 1999 May;65(5):483-90.,Multiple Myeloma,,,,,,,,,,,,
141,752,Thioguanine,Tabloid,Nucleoside/Antimetab: purine antagonist,167,40,mg/m2,PO,,q.d. x 4 wk,0.313,3.13E-07,0.00005233,313 pmol/ml,1.5 h,,586 pmol•hr/L,,,,,1966,"Br J Clin Pharmacol 2001, 51(6): 531",Leukemia: Acute Nonlymphocytic Leukemias,"High variability; Rapidly converted to 6-thioguanylic acid (TGMP).There is technical difficulty in determining plasma concentrations of parent, which are seldom greater than 1 to 2 mcg/mL after a therapeutic oral dose. More significantly, thioguanine enters rapidly into the anabolic and catabolic pathways for purines, and the active intracellular metabolites have appreciably longer half-lives than the parent drug. ",,,,,,,,,,,
142,6396,Thiotepa,Thioplex,Alkylating/DNA damage,189,80,mg,IV,push,,9.660,9.66E-06,0.001828,1828 ng/ml,,2.3 h,4127 ng•hr/ml,419 ml/min,,10%,,1959,Drug Product Label; protein binding found in: Cancer Chemother Pharmacol. 1987;20(4):319-23.,"Breast Cancer:  Adenocarcinoma of the breast, ovary, papillary carcinoma of the urinary bladder.  For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ",Prodrug for TEPA,,,,,,,,,,,
143,9717,* TEPA,(Thioplex),Alkylating/DNA damage,173,as above,,,,,2.039,2.04E-06,0.000353,353 ng/ml,,15.7 h,7452 ng•hr/ml,,,,,1959,Drug Product Label,,metabolite of thioTEPA,,,,,,,,,,,
144,609699,Topotecan HCl  ,Hycamtin ,Topo I,421,2.3,mg/m2,PO,,,0.015,1.49E-08,0.0000063,6.3 ng/ml,,3.49 h,22.7 ng•hr/ml,,,35%,,1996,"Br J Cancer 1999, 80(9): 1380","Small Cell Lung Cancer, relapsed",Data are for topotecan lactone; rapid interconversion between lactone and carboxylate;  Cmax for total (L + C) is 10.2 ng/ml.,,,,,,,,,,,
145,613680,Toremifene  ,Fareston ,Estrogen Receptor Agonist,406,120,mg,PO,,,4.557,4.56E-06,0.00185,1.85 ug/ml,2.9 h,56.5 h,115.1 ug•hr/ml,3.31 L/h,,>99.5%,,1997,Breast Cancer (2009) 16:113–120,Breast Cancer:  metastatic,Dose recommended in label is 60 mg PO,,,,,,,,,,,
146,758246,Trametinib,Mekinist,"kinase inhibitor (Tyrosine/Threonine): MEK1, 2 inhibitor",615,2,mg,PO,,qd,0.021,2.11E-08,0.000013,13.0 ng/ml,2.0 h,3.9-4.8 h,69.7 ng•hr/ml,4.9 L/h,214 L,97.40%,,2013,"Eu J Cancer 2013, 49:2077-2085","melanoma, unresectable or metastatic with BRAF V600E or V600K mutations",approved 05.29.13,,,,,,,,,,,
147,122758,Tretinoin,"Avita, Renova, Atralin, Retin-A, Vesanoid",RAR nuclear receptors,300,45,mg/m2,PO,,,1.155,1.15E-06,0.000347,347 ng/ml,2.2 h,,682 ng•hr/ml,,,>95%,,1995,"Cancer Res 1992, 52(8): 2138; and Drug Product Label",Leukemia: acute promyelocytic leukemia,rapid induction of metabolism reduces Cmax on repeated dosing,,,,,,,,,,,
148,724666,Triptorelin pamoate,Trelstar Depot,LHRH agonist,1311,22.5,mg,IM,,q. 24 wk,0.034,3.36E-08,0.0000441,44.1 ng/ml,1-3 h,,,,30-33 L,0%,,2000,Drug Product Label,"prostate cancer, advanced",,,,,,,,,,,,
149,246131,Valrubicin,Valstar,Topo II,724,800,mg,I Cisternal,,q. wk,0.011,1.11E-08,0.000008,plasma: 8 ng/ml  Bladder: 5-13 uM),2-6 h,,78 nmol•hr/L,,,>99%,,1998,Drugs & Aging 1999 Jul; 15 (1): 69-75,urinary bladder: intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder ,note local delivery intravesicular (bladder); systemic exposure is very low,,,,,,,,,,,
150,760766,vandetanib,Vandetanib,"kinase inhibitor (Tyrosine):  VEGFR, EGFR, RET",475,300,mg,PO,,,2.156,2.16E-06,0.001025,1025 ng/ml,5 h,19 d,20460 ng•hr/ml,13.2 L/h,7450 L,90%,,2011,"Ann Oncol 2009, 20(3): 486; and Drug Product Label",Medullary Thyroid Cancer,,,,,,,,,,,,
151,761431,Vemurafenib  ,Zelboraf ,kinase inhibitor (Tyrosine):  B-Raf ,490,960,mg,PO,,BID,126.551,1.27E-04,0.062,62 ug/ml,3 h,57 h,601 ug•hr/ml,31 L/d,106 L,>99%,,2011,Drug Product Label; see also N Engl J Med. 2010; 363:809-19.,"melanoma, metastatic with BRAF V600E mutation ",,,,,,,,,,,,
152,49842,Vinblastine Sulfate  ,"Velban, Velsar ",Tubulin: microtubule destabilizing,811,1**,mg/m2,IV,,,0.035,3.45E-08,0.000028,28 ug/L **,0.12 h,26.2 h,45 ug•hr/L,0.8 L/h/kg,,98-99%,,1965,"J Pediatr Hematol/Oncol 2006, 28(11): 720","Lymphoma: Generalized Hodgkin’s disease, Lymphocytic lymphoma, Histiocytic lymphoma, Mycosis fungoides, Advanced carcinoma of the testis, Kaposi’s sarcoma, Letterer-Siwe disease (histiocytosis X), Choriocarcinoma resistant to other chemotherapeutic agents, Carcinoma of the breast","Pediatric.  **Low dose: label suggests 3.7-11.1 mg/m2, so this is likely to be a very low estimate of clinically achievable Cmax. ",,,,,,,,,,,
153,67574,Vincristine Sulfate  ,Vincasar PFS ,Tubulin: microtubule destabilizing,825,1,mg/m2,IV,bolus,,0.007,6.52E-09,,6.52 nM,,,,,,75%,,1963,"Cancer Res 1981;41:3551-3555; see liposomal formulations;  J Clin Pharmacol 2006, 46(7): 727; see also Cancer Chemother Pharmacol. 1998;41(5):347-52","Leukemia: acute leukemia;  in combination with other oncolytic agents in Hodgkin’s disease, non-Hodgkin’s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor.",Label suggests 1.5-2 mg/m2 as usual dose,,,,,,,,,,,
154,608210,Vinorelbine Tartrate,Navelbine,Tubulin: microtubule destabilizing,779,25,mg/m2,IV,20 min,,0.811,8.11E-07,0.0006319,631.9 ng/ml,,21.4 h,584.8 ng•hr/mL,78 L/h,,89%,,1994,"Cancer Chemother Pharmacol 2007, 59(3): 407",NSCLC: non small cell lung cancer ,Label recommends up to 30 mg/m2.  Vinorelbine demonstrated high binding to human platelets and lymphocytes; binding to plasma constituents in cancer patients ranged from 79.6% to 91.2%. ,,,,,,,,,,,
155,755986,Vismodegib,Erivedge,Smoothened receptor antagonist/ Hedge Hog inhibitor,421,150,mg,PO,,q.d.,33.900,3.39E-05,,33.9 umol/L,,4 d,5240 umol•hr/L,,,>99%,,2012,"Clin Cancer Res 2011, 17(17): 5774","basal cell carcinoma, metastatic",approved 1/30/12; PK data following 50-57 days of dosing,,,,,,,,,,,
156,701852,Vorinostat  ,Zolinza ,HDAC inhibitor,264,400,mg,PO,,q.d.,1.200,1.20E-06,,1.2 uM,1.5 h,2 h,4.2 umol•hr/L,3945 ml/min,885 L,71%,1.2 uM,2006,"Drug Product Label; also J Clin Oncol. 2005, 23(17): 3923-31",Lymphoma: cutaneous T-cell lymphoma ,"Absorption (AUC) increased approx. 33% by high-fat meal.  I.V. exposure can be 4-15X higher ( 3-10 ug/ml ) see Clin Cancer Res 2003, 9(10): 3578",,,,,,,,,,,
157,606170,Zalcitabine (Dideoxycytidine),Hivid,Nucleoside/Antimetab: Pyrimidine antagonist; reverse transcriptase inhibitor,211,1.5,mg,PO,,,0.119,1.19E-07,0.0000252,25.2 ng/ml,0.8 h,,72 ng•hr/ml,,0.534 L/kg,<4%,,1992,Drug Product Label,not approved for cancer indications;  HIV,not approved for cancer indications;  approved for HIV treatment; discontinued 2006; PK from dose recommended for HIV treatment,,,,,,,,,,,
158,721517,Zoledronic Acid  ,Zometa ,Farnesyl Pyrophosphate Synthase Inhibitor,272,4,mg,IV,15 min,,0.971,9.71E-07,0.000264,264 ng/ml,,146 h,420 ng•hr/ml,,,33-40%,,2001,"J Clin Pharmacol 2002, 42(11): 1228",hypercalcemia of malignancy; multiple myeloma;  documented bone metastases from solid tumors,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
could not find reliable data for the following agents; some are discontinued ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,9706,Triethylenemelamine,,Alkylating/DNA damage,204,,,,,,,,,,,,,,,,,,,,not in FDA Orange Book,,,,,,,,,,,
,25154,Pipobroman,Vercyte,Alkylating/DNA damage,356,,,,,,,,,,,,,,,,,,,,discontinued,,,,,,,,,,,
,34462,Uracil mustard,Uramustine,Alkylating/DNA damage,252,,,,,,,,,,,,,,,,,,,,discontinued,,,,,,,,,,,
,9701,Methyltestosterone,"Testred, Android",Androgen Receptor Agonist/ Aromatase Inhibitor,302,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,249008,Trimetrexate,Neutrexin,Nucleoside/Antimetab: DHFR inhibitor,369,,,,,,,,,,,,,,,,,,,,discontinued:  must be administered with leucovorin,,,,,,,,,,,
,24559,Plicamycin,"Mithracin, Mithramycin A",Topo /DNA binding,1085,,,,,,,,,,,,,,,,,,,,discontinued,,,,,,,,,,,
